Introduction

Dolutegravir is the common thread running through two distinct HIV medicines marketed by ViiV Healthcare, the specialist company majority-owned by GSK plc (LSE:GSK). Tivicay contains dolutegravir as a single agent used alongside other antiretrovirals, while Dovato pairs dolutegravir with lamivudine in a fixed-dose, two-drug single-tablet regimen. Both are approved and currently marketed in the UK, EU and US.

For investors, the central question is why this franchise matters. Dolutegravir-based regimens sit at the core of GSK's Specialty Medicines HIV business, a material contributor to group revenue. GSK retains a 78.3% economic interest in ViiV Healthcare following 2026 shareholding changes. This article examines the products, the case for two-drug regimens, the competitive landscape, and the clinical, regulatory and commercial factors that could shape future demand.

Which products contain dolutegravir?

Dolutegravir is an HIV integrase strand transfer inhibitor, or INSTI. According to the approved product information, it binds the integrase active site and blocks the strand-transfer step of retroviral DNA integration, a step essential to the HIV replication cycle (Tivicay Summary of Product Characteristics).

Within the ViiV Healthcare portfolio, dolutegravir features across several brands. Tivicay is the dolutegravir single-component product, given in combination with other antiretroviral medicines. Dovato combines dolutegravir with lamivudine, a nucleoside reverse transcriptase inhibitor whose active triphosphate incorporates into viral DNA and causes chain termination (Dovato SmPC).

The same molecule also appears in other ViiV regimens such as Triumeq and Juluca. A UK regulatory product file, or a substance entry in a medicines register, simply evidences that an authorised product exists; it is not, by itself, proof of new approval, ownership, launch or commercial success. The verified authorisations here rest on the electronic medicines compendium SmPCs for Tivicay and Dovato.

How do Tivicay and Dovato differ?

The clearest distinction is composition. Tivicay is dolutegravir alone and must be combined with other antiretroviral agents to form a complete regimen. Dovato is a self-contained two-drug regimen of dolutegravir 50 mg plus lamivudine 300 mg in a single daily tablet.

That difference drives how each is positioned. Tivicay offers flexibility as a backbone INSTI within multi-drug combinations, including in younger and lower-weight paediatric patients. Dovato is designed as a complete single-tablet treatment that reduces the number of antiretroviral classes a patient takes, subject to labelling restrictions.

The two therefore address overlapping but not identical needs. Tivicay supports individualised combination therapy where a clinician selects the accompanying agents, whereas Dovato provides a fixed, simplified option for eligible patients. Both remain on-patent in the US and EU, with no branded-market generic identified for either.

What approved treatment populations are covered?

Approved populations differ by product and must not be merged across regions. In the UK, Tivicay is indicated, in combination with other antiretrovirals, for the treatment of HIV-infected adults, adolescents and children at least 6 years of age and weighing at least 14 kg (emc SmPC, product 10057).

Dovato in the UK is indicated for HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class or to lamivudine (emc SmPC, product 10446). The EU centralised authorisations align with these UK indications.

US labelling is framed differently. Tivicay is approved in combination therapy for HIV-1 in adults and paediatric patients weighing at least 14 kg, with dosing and eligibility differing for INSTI-naive versus INSTI-experienced patients. In the US, Dovato is a complete regimen for treatment-naive patients or as a switch for those virologically suppressed with no history of treatment failure and no known relevant resistance; a 2024 approval extended it to adolescents. Investors should note the US paediatric weight threshold reference of at least 25 kg differs from the UK/EU threshold of at least 40 kg and above 12 years.

What is the strategic case for two-drug HIV regimens?

The strategic rationale for two-drug regimens such as Dovato is to maintain treatment goals while reducing the number of antiretroviral classes a person takes over what can be a lifelong course of therapy. The clinical logic centres on limiting cumulative drug exposure for eligible patients.

This positions Dovato as a differentiator against three- and four-drug single-tablet regimens. Where a patient meets the labelled criteria, a simplified regimen may support long-term adherence and offers a distinct commercial proposition within the crowded oral HIV market.

The caution is important. A two-drug regimen is not suitable for every person living with HIV. Eligibility is defined by approved labelling and clinician judgement, and Dovato's UK label specifically excludes patients with known or suspected resistance to the integrase inhibitor class or to lamivudine. The two-drug approach is a strategic pillar for ViiV, but its addressable population is bounded by those criteria.

What commercial role does dolutegravir play?

GSK reports HIV as a core franchise within its Specialty Medicines segment, delivered through ViiV Healthcare. Dolutegravir-based regimens, including Dovato, Triumeq and Tivicay, together with long-acting cabotegravir, constitute the substance of that HIV business.

Ownership matters for how investors read the economics. Following the agreement announced on 20 January 2026 and completed around April 2026, GSK retains a 78.3% economic interest in ViiV Healthcare, Shionogi increased its stake to 21.7%, and Pfizer exited entirely. Under the transaction ViiV issued new shares to Shionogi for USD 2.125bn, Pfizer received USD 1.875bn, and GSK received a special dividend of USD 0.250bn (GSK press release, 20 January 2026).

On scale, the HIV franchise is a material contributor to GSK group revenue, but specific product-level revenue, market-share and growth figures are not reproduced here. Where product revenue is disclosed, it appears in GSK's quarterly results and annual report, and investors may wish to take those numbers directly from GSK's latest announcements rather than rely on estimates.

What competition and resistance considerations remain?

Competition in oral HIV therapy is intense. Gilead Sciences' Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is the leading single-tablet INSTI regimen and Dovato's principal competitor, alongside other TAF-based regimens such as Genvoya, Descovy and Odefsey. Merck & Co markets Delstrigo and Pifeltro and is advancing an islatravir-based pipeline.

There is also internal portfolio dynamics to weigh. ViiV's own long-acting injectable Cabenuva (cabotegravir/rilpivirine), plus Triumeq and Juluca, compete for the same patient pool as the daily oral dolutegravir products.

Resistance is a defining clinical consideration. Dovato's approved use is restricted where there is known or suspected resistance to the integrase inhibitor class or to lamivudine, which shapes eligibility. In lower- and middle-income markets, generic dolutegravir, notably the fixed-dose TLD combination, is widely available through voluntary licensing via the Medicines Patent Pool, a different competitive dynamic from the on-patent US and EU branded markets.

What could affect future demand?

Several structural factors could shape demand. Over time, patent expiry and generic erosion represent a long-term threat to dolutegravir franchise revenue, even though no branded-market generic of Tivicay or Dovato has been identified to date and both remain on-patent in the US and EU.

A broader shift from daily oral regimens toward long-acting injectables could influence oral dolutegravir volumes, potentially including some cannibalisation by ViiV's own Cabenuva. Pricing and reimbursement pressure from NICE and the NHS in the UK, and from US payers, adds further uncertainty, as do access and voluntary-licensing dynamics in lower-income markets.

Concentration risk is relevant too. GSK's HIV business is heavily reliant on this franchise within Specialty Medicines, and governance now reflects Shionogi's larger 21.7% minority interest. Regulatory, pharmacovigilance and litigation matters, including the historical dolutegravir safety signal reflected in labelling, remain part of the risk picture. Commercial performance will ultimately depend on competitive positioning, clinical guidelines and payer decisions.

What should investors monitor?

Investors following LSE:GSK may wish to track ViiV Healthcare product disclosures in GSK's quarterly results and annual report, where HIV franchise trends are reported. Movements in Dovato and broader dolutegravir performance relative to competing regimens can indicate how the two-drug strategy is faring.

Pipeline progress in long-acting therapies is a second area to watch, since it could both extend and reshape the franchise. Regulatory updates, label changes and guideline positioning across the UK, EU and US will also influence eligible populations.

Finally, the completed 2026 shareholding structure, with GSK at 78.3% and Shionogi at 21.7%, is worth noting for how ViiV's economics flow to GSK. None of this constitutes advice to buy, sell or hold; it simply identifies factors relevant to understanding the franchise.

Information verified as at: 14 July 2026, 5:00 pm (UK time, BST).